Navigation Links
Novocure™ to Present NovoTTF™ Therapy Data at the 2012 Annual Scientific Meeting of the American Society of Clinical Oncology
Date:5/29/2012

e Xian Lee, Beth Israel Deaconess Medical Center, Boston, MA  Publication number: e21078

Principal Author:   Dr. Moshe Giladi, Novocure Ltd. Haifa, Israel
Publication number:  e14616

About Glioblastoma

Glioblastoma (GBM) is the most aggressive and most common form of primary brain tumor in the U.S. The disease affects approximately 10,000 Americans each year.  Historically, based on literature, the median overall survival time from initial diagnosis is 15 months with optimal treatment, and median survival from the time of tumor recurrence is only 3-5 months without additional effective treatment.  The disease is widely recognized as one of the deadliest forms of cancer.

About the NovoTTF™-100A System

NovoTTF™-100A System is a portable, non-invasive medical device designed for continuous use throughout the day by the patient.  The device has been shown in both in vitro and in vivo studies to slow and reverse tumor growth by inhibiting mitosis, the process by which cells divide and replicate.  The NovoTTF-100A device, which weighs about six pounds (three kilograms), creates a low intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death prior to division.  In patients with recurrent glioblastoma brain tumors, the device has shown clinical efficacy comparable to that of active chemotherapies with better quality of life and without many of the side effects of chemotherapy.  The NovoTTF-100A has recei
'/>"/>

SOURCE Novocure
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
5. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
8. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
9. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
10. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
11. ViroPharma to Present at Three Upcoming Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... CHAPEL HILL, N.C. , Aug. 29, 2014 /PRNewswire/ ... the face of regulatory and marketplace changes. CI leaders ... flounder. In a new Best Practices, ... a host of actionable insights, including: - ... and cheaper than primary research - Internal ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 /PRNewswire/ ... Medina Medical as CEO and member of the Board ... three decades of medical device development and commercialization experience, ... Medical,s field. Mr. Engelson previously served as a Partner ... served as President and CEO of two Foundry start-ups. ...
(Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2US CNS Disorders Drug Pipeline Insight 2014 2
... Owner Pleads Guilty; Dog Wardens Revoke,Snyder County Kennel ... officials are cracking down on unsatisfactory kennels with ... prosecutor and dog,wardens, Special Deputy Agriculture Secretary for ... dog wardens continue to make progress enforcing current,regulations. ...
... Corp.,(Nasdaq: GENZ ) announced today that the ... trial examining the safety and effectiveness of,Clolar(R) (clofarabine) ... leukemia (AML) who are unlikely to benefit from ... to provide substantial,evidence for expanding the current product ...
Cached Medicine Technology:Dog Law Officers' Crackdown on Unsatisfactory Kennels Protecting Animals, Consumers 2Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML 2Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML 3Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML 4Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML 5Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML 6
(Date:8/30/2014)... August 30, 2014 McLeod's Sunset Park ... auto repair shop with strong ties to the community celebrates ... happy to announce they have been chosen by The ... for auto repair. , Tim McLeod’s father, Norris (most ... sixty years ago. Although his son, Tim runs the day ...
(Date:8/30/2014)... Franklin, TN (PRWEB) August 30, 2014 ... techniques, including nine mobilizations and six muscle energy techniques. ... also narrates and demonstrates twenty-seven examination techniques for the ... course supports Dr. Reiman's live course presentation with ... Objectives, Applying a differential diagnosis ...
(Date:8/30/2014)... August 30, 2014 What challenges exist ... are the latest trends, concerns, and considerations? Sports ... Ken Pendleton recently spoke with Woody Wommack, Southeast Football ... current issues in football recruiting. Notably, Wommack spoke ... athletes, changes that he thinks are coming as a ...
(Date:8/30/2014)... A new sudden death predictor for patients with ... defibrillators (ICDs) in ESC Guidelines published today. They ... Chairperson Professor Perry Elliott (UK). , The "2014 ... Cardiomyopathy" are published today on-line in the ... ESC Website. Previous ESC Guidelines on hypertrophic cardiomyopathy ...
(Date:8/29/2014)... San Diego (PRWEB) August 30, 2014 ... and their loved ones and caretakers. Author Eddie M. Leung ... with cholangiocarcinoma or bile duct cancer, a very ... “The Year That Changed My Life” (published by Xlibris), he ... but more importantly, he imparts a survivor’s testimony that this ...
Breaking Medicine News(10 mins):Health News:McLeod's Sunset Park Auto Service Celebrates 60 Years Honored with Best of South Tampa 2Health News:North American Seminars Online PT Continuing Education Course, Examination and Treatment of the SI Joint, Receives Continuing Education Approval in NJ, CA, IL, PA, & TX 2Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 2Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 3Health News:Sudden death predictor identifies ICD candidates in new ESC Guidelines 2Health News:Eddie M. Leung Shares His Testimony As a Survivor of Cancer 2Health News:Eddie M. Leung Shares His Testimony As a Survivor of Cancer 3
... a roadside and rushed to the University of Rochester Medical Center ... doctors were surprised to discover that a trendy tea derived from ... URMC team reported the case study, believed to be the first ... Journal of Emergency Medicine . They described it as ...
... FL (For immediate release) -- Cotinine, a compound derived from ... in a mouse model of Alzheimer,s disease, a study led ... University of South Florida found. The findings are ... in advance of print publication. "We found a compound ...
... the manufacturer of the Alzheimer,s drug memantine submitted a supplementary ... Efficiency in Health Care (IQWiG) sees proof of a benefit ... of a benefit for activities of daily living, at least ... conclusions of the first IQWiG benefit assessment of 2009. IQWiG ...
... Colonoscopy is regarded as the most thorough way ... life-saving procedure can also be painful. Scientists and ... to reduce patient discomfort while also ensuring the ... School of Engineering led by Associate Professor of ...
... Pain researchers from the Sheikh Zayed Institute for Pediatric ... that resiniferatoxin, a drug that has shown early promise as ... body,s ability to fight off bacterial infections, particularly sepsis. ... of the journal Anesthesiology , sheds new light on ...
... percent of American families living above the federal poverty ... the Affordable Care Act, according to a new Commonwealth ... the Massachusetts Institute of Technology (MIT). The report finds ... under the law will make premiums affordable for most ...
Cached Medicine News:Health News:Medical sleuthing linked muscle, kidney problems to kava tea 2Health News:Medical sleuthing linked muscle, kidney problems to kava tea 3Health News:Tobacco-derived compound prevents memory loss in Alzheimer's disease mice 2Health News:Long struggle for appropriately processed manufacturer data leads to a new assessment of memantine 2Health News:Long struggle for appropriately processed manufacturer data leads to a new assessment of memantine 3Health News:A less painful colonoscopy 2Health News:A less painful colonoscopy 3Health News:Study: Resiniferatoxin may increase sepsis-related mortality 2Health News:New study: Health reform to make health insurance affordable for nearly all families 2
The ACE Alera clinical chemistry system serves a wide variety of chemistry diagnostic needs with the power of a large floor model analyzer in an easily integrated and economizing compact footprint of...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: